## GLW: Corning Incorporated - XLK: Technology

### Executive Summary

STRENGTH thesis confirmed: MRS_10 at 3.7% in lower entry zone (3.0-6.0%), top quartile (85th pct) cross-sectional ranking. Short-term MRS_5 (3.2%) confirms momentum alignment. Strong momentum (+4.0% 5-day acceleration). Outperforming sector by 2.5%.

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($82.33)
- **If Wrong:** Exit if MRS_10 drops below entry zone or breaks stop
- **Invalidation:** MRS_10 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 6
- **Sentiment:** Neutral (Bullish: 1, Bearish: 0)

**1. High Throughput Screening Market Top key Players 2035 | Agilent**
- Source: openPR.com | 20251207T152528 | Bullish | Relevance: 85%
- The High Throughput Screening (HTS) Market, driven by the demand for rapid drug discovery and technological advancements, reached USD 23.26 Billion in 2024 and is projected to grow to USD 64.40 Billion by 2035 with a CAGR of 9.70%. Key players like Agilent and Merck KGaA are benefiting from increasing R&D investments, automation, and the integration of AI, which are crucial for accelerating drug development processes across various therapeutic areas. North America leads the market, while Asia-Pacific is emerging as the fastest-growing region due to expanding research and funding initiatives.

**2. Diana Shipping locks charter deal for capesize with Glencore**
- Source: Shipping Telegraph | 20251208T014027 | Neutral | Relevance: 65%
-  Diana Shipping has secured a time charter contract with Glencore Freight Pte. Ltd. for its capesize vessel, the P. S. Palios, at a gross charter rate of $25,200. This deal is expected to generate approximately $8.34 million in gross revenue for Diana Shipping. The company's fleet currently comprises 36 dry bulk vessels, with two methanol dual-fuel newbuilding kamsarmax vessels expected by 2027 and 2028.

**3. Russell Investments Group Ltd. Sells 86,034 Shares of Revolution Medicines, Inc. $RVMD**
- Source: MarketBeat | 20251206T042421 | Neutral | Relevance: 63%
-  Russell Investments Group Ltd. has reduced its stake in Revolution Medicines (NASDAQ:RVMD) by 31.1%, selling over 86,000 shares, though it still holds shares worth nearly $7 million. Despite recent insider selling totaling over $17 million and negative earnings, analysts maintain a "Buy" rating with an average price target of $78.50 for the clinical-stage oncology company. Revolution Medicines continues to develop targeted therapies for RAS-addicted cancers.

**4. Does Navitas Semiconductor (NVTS) Have a Durable Edge With Its New AEC-Plus SiC Strategy?**
- Source: Simply Wall Street | 20251206T043154 | Neutral | Relevance: 58%
-  Navitas Semiconductor recently introduced new ultra-high voltage SiC products and an "AEC-Plus" reliability benchmark, targeting demanding applications like grid infrastructure and AI data centers. While these advancements strengthen the company's long-term positioning and manufacturing capabilities, near-term growth catalysts and the risk of ongoing losses remain key factors for investors. Community fair value estimates for Navitas stock show significant divergence, highlighting the importance of diverse perspectives in assessing its investment potential.

**5. KKR & Co. Inc. $KKR Shares Acquired by California Public Employees Retirement System**
- Source: MarketBeat | 20251208T094900 | Neutral | Relevance: 58%
-  The California Public Employees Retirement System increased its stake in KKR & Co. Inc. by 5.8%, acquiring an additional 62,566 shares. This brings their total holdings to 1,145,391 shares, valued at approximately $152.37 million. Despite recent price target trims by analysts, KKR maintains a "Moderate Buy" consensus rating with a target price of $156.31, following strong Q2 earnings where it beat EPS estimates and reported $4.36 billion in revenue.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-21 | UBS | $109 | $100 | +9% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-21 | UBS | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 9 ($0.45M) |
| Sells | 6 ($13.55M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 1 |

**Top Holders:**
- Vanguard Group Inc: 11.5% (+0.8%)
- Blackrock Inc.: 7.7% (+4.1%)
- State Street Corpora: 4.3% (+1.2%)
- JPMORGAN CHASE & CO: 3.5% (+142.7%)
- Bank of America Corp: 2.4% (-2.1%)

### Key Risks

1. Heavy insider selling: $14M sold (6 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Momentum building: MRS_10 improving +4.0% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.70 indicates undervaluation relative to growth. Analyst sentiment positive (1 raises, avg +9%). Insider selling cluster ($13.6M in 90 days), potential headwind. Institutional flow bullish (8 buying vs 1 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $75.7B |
| Beta | 1.11 |
| 52W Range | $37.31 - $92.57 |
| Short Interest | 2.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.70 |
| Forward P/E | 28.7 |
| Current P/E | 35.0 |
| YoY Growth | 22.1% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -0.3% to 3.7% (+4.0% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (3.0-6.0%), cross-sectional ranking at 85th percentile. MRS_5 at 3.2% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.56), confirming momentum.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 3.71% (CS: 85) | Strong |
| RSI_14 | 60.6 | Neutral |
| MACD Histogram | 0.56 | Bullish |
| vs SMA20 | 1.055x | Above |
| vs SMA50 | 1.039x | Above |
| vs SMA200 | 1.423x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $88.27
- **Stop Loss:** $82.33 (6.7% risk)
- **Target:** $97.18 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 202
- **Position Value:** $17,830.54
- **Portfolio %:** 17.83%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

### Earnings

**Next:** 2026-01-28 (Est: $0.70)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.66 | $0.67 | +0.8% |
| 2025Q2 | $0.57 | $0.60 | +5.1% |
| 2025Q1 | $0.51 | $0.54 | +5.4% |
| 2024Q4 | $0.56 | $0.57 | +2.1% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*